Jazz Pharmaceuticals is teaming with AbCellera in a deal worth more than $2.4 billion to discover multispecific T-cell engaging antibodies for gastrointestinal cancers and other solid tumours, with AbCellera leading the first 2 programmes and committing to a third within a year. The partnership gives Jazz exclusive worldwide options on each candidate and could pay AbCellera up to $792 million per programme, plus royalties, as Jazz expands its GI oncology pipeline beyond zanidatamab.

Why It Matters To Oncology

• Multispecific antibodies are a major drug discovery focus because they can combine CD3 binding, costimulatory signalling and tumour targeting to redirect T cells against hard-to-treat solid tumours.

• GI cancers remain a high-need area where T-cell engagers have shown promise but still face challenges including efficacy, selectivity and tolerability in the solid tumour microenvironment.

• For clinicians, this signals continued industry investment in next-generation immune engagers that may eventually broaden options for patients with malignant neoplasm of the GI tract and other solid tumours.

The Financials

• AbCellera gets $56 million upfront for the first 2 programmes, with another $28 million due when the third programme starts.

• The headline value exceeds $2.4 billion, driven largely by downstream option fees and development, regulatory and commercial milestones.

• If Jazz advances candidates, AbCellera could receive up to $792 million per programme, plus tiered royalties in the mid-single to low-double digits.

What They're Saying

• Jazz oncology CSO Josh Allen said the collaboration aligns with the company’s rare disease strategy while expanding its focus on GI cancers and building on existing oncology expertise.

• The companies are positioning AbCellera’s discovery platform as a way to generate T-cell engagers for tumour types that have been difficult to crack with conventional approaches.

• The move also reinforces Jazz’s intent to build around GI oncology following the 2024 accelerated FDA approval of zanidatamab in previously treated biliary tract cancer.

What's Next

• AbCellera will run discovery and early preclinical work on the initial 2 T-cell engager programmes and is slated to initiate a third within 12 months.

• Jazz can opt into clinical development and global commercialisation for each candidate, and the alliance could expand by up to 2 additional programmes.

• Separately, Jazz is awaiting an FDA decision by Aug. 25 on zanidatamab in first-line gastroesophageal adenocarcinoma after the drug beat trastuzumab in a Phase III study last year.